← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Institute For Molecular Medicine
Huntington Beach, CA
$45,280,607
Total funding
10
Grants
Funding over time
peak $9.4M · FY2008–25$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$45,280,607 · 10
By mechanism
R01$22,290,248 · 5
U01$19,170,731 · 3
RF1$3,340,325 · 1
R21$479,303 · 1
Investigators at Institute For Molecular Medicine
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
FDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants.$5,308,961
R01 · FY2025 · AG
Multiple Approaches to Abeta Vaccination in Animal Models$3,340,325
RF1 · FY2018 · AG
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.$2,680,709
R01 · FY2022 · AG
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.$2,408,617
R01 · FY2023 · AG
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.$2,288,273
R01 · FY2025 · AG
Manufacturing of Drug Product, Dual Aβ/tau Vaccine for Clinical Trials$2,270,000
U01 · FY2023 · AG
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.$2,243,861
R01 · FY2024 · AG
IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial$2,237,972
U01 · FY2022 · AG
IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)$1,849,047
U01 · FY2025 · AG
IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)$1,791,614
U01 · FY2024 · AG
IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial$1,672,856
U01 · FY2021 · AG
IND-enabling Preclinical Studies for Aβ and Dual Aβ/Tau MultiTEP platform-based AD Vaccines$1,346,072
U01 · FY2021 · AG
IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial$1,272,333
U01 · FY2020 · AG
Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND$1,253,815
U01 · FY2017 · AG
Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND$1,174,622
U01 · FY2016 · AG
Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND$1,152,198
U01 · FY2015 · AG
IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial$1,116,260
U01 · FY2019 · AG
Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND$927,669
U01 · FY2018 · AG
Manufacturing of New Batch AV-1959D Drug Product and Placebo for Phase 1 Trial$699,000
R01 · FY2023 · AG
Combining AD Epitope Vaccine with Innate Immunity$646,763
R01 · FY2014 · NS